Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15756737 | 1.00 | FOLH1 (0.54) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL29893406 | 0.98 | FOLH1 (0.53) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL8821210 | 0.98 | FOLH1 (0.53) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL8821211 | 0.98 | FOLH1 (0.53) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL30932293 | 0.94 | FOLH1 (0.49) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL27204494 | 0.93 | FOLH1 (0.48) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL27164811 | 0.93 | FOLH1 (0.48) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| Glycylglycylglycine SCHEMBL2567025 | 0.91 | FOLH1 (0.52) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL32672545 | 0.90 | NMT1 (0.51) | FOLH1SLC6A5SLC15A2 | |
| SCHEMBL7797130 | 0.89 | SLC15A2 (0.49) | FOLH1SLC6A5SLC15A2CPB2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025031383-A1 | BIFUNCTIONAL LINKER COMPOUND, ANTIBODY DRUG CONJUGATE, PREPARATION METHOD FOR ANTIBODY DRUG CONJUGATE, AND USE OF ANTIBODY DRUG CONJUGATE | 杭州爱科瑞思生物医药有限公司 | 2025-02-13 | — | — | WO | claimed |
| CN-115925788-A | Anglerfish swim bladder antioxidant peptide for treating non-alcoholic fatty liver disease and preparation method and application thereof | 浙江海洋大学 | 2023-04-07 | — | — | CN | claimed |
| EP-3818072-A1 | MEANS AND METHODS FOR SITE-SPECIFIC PROTEIN MODIFICATION USING TRANSPEPTIDASES | Technische Universität München (DE) | 2021-05-12 | — | — | EP | claimed |
| WO-2020007899-A1 | MEANS AND METHODS FOR SITE-SPECIFIC PROTEIN MODIFICATION USING TRANSPEPTIDASES | Technische Universität München (DE) | 2020-01-09 | — | — | WO | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| EP-4696700-A1 | LONG-ACTING K-OPIOID RECEPTOR AGONIST | Chengdu Aoda Biotechnology Co., Ltd (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025031383-A1 | BIFUNCTIONAL LINKER COMPOUND, ANTIBODY DRUG CONJUGATE, PREPARATION METHOD FOR ANTIBODY DRUG CONJUGATE, AND USE OF ANTIBODY DRUG CONJUGATE | 杭州爱科瑞思生物医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-02-04 | — | — | US | disclosed |
| US-12180299-B2 | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use | ADIMAB, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2020007899-A1 | MEANS AND METHODS FOR SITE-SPECIFIC PROTEIN MODIFICATION USING TRANSPEPTIDASES | Technische Universität München (DE) | 2020-01-09 | — | — | WO | disclosed |
| US-9868781-B2 | Antibodies for ubiquitinated proteins | CORNELL UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9751911-B2 | Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-05 | — | — | US | disclosed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | disclosed |
| US-20090317409-A1 | Antibodies for ubiquitinated proteins | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317409-A1 | Antibodies for ubiquitinated proteins | UBQLN1, STUB1, UBAP2 | FOLH1 1865/4885SLC6A5 4646/4885SLC15A2 4551/4885 |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | ASGR1, GNRHR, SCTR | FOLH1 22/4885SLC6A5 1181/4885SLC15A2 983/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FOLH1 22/4885SLC6A5 1181/4885SLC15A2 983/4885 |
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | FOLH1 2388/4885SLC6A5 4187/4885SLC15A2 1915/4885 |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | FOLH1 2756/4885SLC6A5 2870/4885SLC15A2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.